Home › Korean Stocks › Raphas

Raphas: Korean regulator returns Phase 2b/3 trial application for allergic rhinitis immunotherapy DF19001

Raphas (라파스) · KOSDAQ 214260 · Material management matter (clinical) · Filed 2026-11-20 · Summary published 2026-11-21

For reference only, not investment advice.This is a factual summary of a company filing. It is not a recommendation to buy, sell or hold any security. Read the original filing on DART before making any decision. Full disclaimer

What was filed

Raphas disclosed that the Ministry of Food and Drug Safety (MFDS) returned its application to start a Phase 2b/3 trial of DF19001, an immunotherapy for American house dust mite allergic rhinitis.

Key facts

ProductDF19001, allergic rhinitis immunotherapy
Planned trialPhase 2b/3, 52-week, multicentre, randomised, double-blind, placebo-controlled
Reason givenRequest to supplement the trial protocol and data on manufacturing and quality of the investigational drug
Company's next stepReview the reasons and re-apply for IND approval
Date notified20 Nov 2026

Context

The company states the return relates to protocol and manufacturing/quality documents, not to the safety and immunogenicity data from its earlier Phase 1 trial.

Original filing: DART receipt no. 20261120900961 (Korean)

Figures are taken from the filing as submitted. KRW conversions use the exchange rate stated in the filing. Filings can be corrected later; the DART version prevails.